Following CNR2 activation, we observed inhibition of breast cancer growth, suppression of EGF/EGFR as well as IGF-I/IGF-IR signaling pathways and their related tumorigenic events in vitro and in vivo. This evidence concerns the gene EGFR and breast carcinoma.